U.S. stocks lower as investors rotate out of tech ahead of Jackson Hole
NORTH CHICAGO - AbbVie (NYSE:ABBV), a $365 billion market cap biotechnology giant with over $58 billion in annual revenue, announced Tuesday it has completed its acquisition of Capstan Therapeutics, adding a potential first-in-class targeted lipid nanoparticle therapy to its portfolio.
The acquisition brings Capstan’s lead asset CPTX2309, currently in Phase 1 clinical trials for B cell-mediated autoimmune diseases, under AbbVie’s control. The therapy uses targeted lipid nanoparticle technology to generate CD19-specific, CD8+ in vivo CAR-T cells designed to achieve B cell depletion without requiring lymphodepleting chemotherapy. According to InvestingPro data, AbbVie maintains a robust 71% gross profit margin, supporting its continued investment in innovative therapies.
"With the acquisition now complete, we are excited to work together with the talented team at Capstan to advance our mission of transforming patient care," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research at AbbVie.
The deal strengthens AbbVie’s immunology pipeline with technology aimed at in vivo cell programming. CPTX2309 is designed to potentially achieve durable, drug-free remission while avoiding challenges associated with conventional ex vivo CAR-T therapies.
AbbVie did not disclose the financial terms of the acquisition in the press release statement.
The company focuses on several therapeutic areas including immunology, oncology, neuroscience, and eye care, along with products in its Allergan Aesthetics portfolio. With 13 analysts recently revising earnings estimates upward and the stock trading near its 52-week high, InvestingPro analysis reveals multiple positive indicators for AbbVie’s growth trajectory. Subscribers can access over 30 additional ProTips and a comprehensive Research Report covering AbbVie’s complete financial picture.
In other recent news, AbbVie has reported its second-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of $2.97, slightly above the forecast of $2.96. The company’s revenue also exceeded projections, coming in at $15.4 billion compared to the expected $14.99 billion. Cantor Fitzgerald responded to these strong results by raising its price target for AbbVie to $215, noting the impressive performance of Skyrizi sales. Additionally, AbbVie announced a $195 million investment to expand its North Chicago manufacturing facilities, enhancing its capabilities in neuroscience, immunology, and oncology medicines. Piper Sandler has initiated coverage of AbbVie with an Overweight rating and a price target of $231, citing the company’s minimal exposure to loss of exclusivity issues. Meanwhile, Bernstein has reiterated its Market Perform rating with a price target of $203, following AbbVie’s significant earnings and revenue beat. These developments reflect a period of robust activity and strategic investment for the pharmaceutical company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.